Immunology

NuSepin is the intravenous formulation of HY209, which modulates the GPCR19-P2X7R axis to inhibit the activation of the NLRP3 inflammasome. It is being developed as a treatment for sepsis, a systemic inflammatory response syndrome (SIRS). A Phase 2b clinical trial was completed in patients with COVID-19 pneumonia across 39 sites in five countries, including Europe and South Korea.

Following the end of the COVID-19 pandemic, the development plan has shifted toward the broader indication of SIRS. NuSepin is currently being developed as a therapeutic agent to suppress cytokine storms and uncontrolled inflammatory responses that may occur during surgical procedures.

In a mouse model of sepsis, NuSepin administration led to the recovery of liver and kidney tissues damaged by cytokine storms, improving survival rates to 70–80%. Additionally, in a beagle dog model of sepsis, NuSepin demonstrated efficacy in preventing organ damage, suppressing pro-inflammatory cytokines, and increasing survival rates.